Dicot AB

DICOT

SE0011178458

Pharmaceuticals

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.248 ^SEK	-0.20%		+16.71%	-22.01%

Apr. 23	Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study	CI
Mar. 11	Dicot AB Announces Recruitment Completed in Dicot's Phase 1 Trial	CI

Dicot's CEO tells BioStock: "Several prominent people want to be part of the journey"

February 29, 2024 at 03:16 am EST

Uppsala-based Dicot recently released its year-end report. CEO Elin Trampe notes that there is great confidence in the company's research, both among investors and researchers in the field. BioStock contacted her in connection with the report to get a comment on the latest news and to find out more about what's on this spring's to-do list.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/02/dicots-ceo-several-prominent-people-want-to-be-part-of-the-journey/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/dicot-ab--publ-/r/dicot-s-ceo-tells-biostock---several-prominent-people-want-to-be-part-of-the-journey-,c3937581

Latest news about Dicot AB

Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study	Apr. 23	CI
Dicot AB Announces Recruitment Completed in Dicot's Phase 1 Trial	Mar. 11	CI
Dicot AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 26	CI
Dicot AB Presents Positive Results from the First Part of its Phase 1 Clinical Study	Jan. 23	CI
Dicot Files New Manufacturing Technology Patent in Sweden; Stock Rises	Jan. 11	MT
Dicot Applies for Patent Covering New Manufacturing Technology	Jan. 11	CI
Dicot AB Announces Partial Results from Phase 1 Trial to Be Presented Early Next Year	Dec. 15	CI
Dicot AB Initiates Repeat Dosing in its Clinical Study	Nov. 14	CI
Dicot AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Dicot Sets TO5 Warrant Exercise Price in Rights Issue	23-10-30	MT
Dicot AB Initiates Repeated Dosing in Phase I Study	23-10-24	CI
The Second Part of Dicot's Phase 1 Study Starts on October 20, 2023	23-10-20	CI
Swedish Pharma Company Dicot Files Application under Patent Cooperation Treaty	23-09-26	MT
Dicot AB Applies for International Patent Protection	23-09-26	CI
Dicot AB Announces First Participants Dosed in Phase 1 Trial	23-09-04	CI
Dicot AB Applies for US Patent	23-08-29	CI
Dicot AB Announces Clinical Phase 1 Study Starts	23-08-25	CI
Dicot AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Dicot AB Receives Approval to Start Phase 1 Clinical Trial	23-08-15	CI
Certain Common Shares of Dicot AB are subject to a Lock-Up Agreement Ending on 26-JUL-2023.	23-07-25	CI
Dicot AB Submits Application to Start Clinical Phase 1 Trial	23-06-01	CI
Dicot AB Announces Success in Collaboration with Uppsala University and W. Szafer Institute of Botany	23-05-31	CI
Dicot to Seek Initiation of a Phase I Clinical Trial for the Drug Candidate Lib-01	23-05-23	CI
Dicot AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-19	CI
Dicot's Study Drug Arrives in Sweden	23-05-17	CI

Chart Dicot AB

Duration

Period

More charts

Company Profile

Dicot AB is a manufacturer of pharmaceutical preparation. The Company is located in Uppsala, Sweden.

Sector

Pharmaceuticals

Calendar

2024-05-02 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DICOT AB	-22.01%	18.49M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B